An experimental weight-loss injection developed in China, known as ribupatide, has shown results that could rival established drugs like Wegovy and Mounjaro. A recent study indicated that patients using the once-weekly jab lost an average of 17.7 percent of their body weight in just under a year.
In the trial published in the journal JAMA, researchers from Fudan University in Shanghai recruited 567 overweight or obese adults. Participants receiving weekly injections of ribupatide at doses of 2mg, 4mg, or 6mg were compared to a placebo group. After 48 weeks, those on the lowest dose lost an average of 10.7 percent of their body weight, while the middle dose group shed 16.4 percent, and the highest dose group achieved 17.7 percent weight loss. In contrast, the placebo group only lost 1.4 percent.
Further analysis revealed that nearly half of the participants on the highest dose lost more than a fifth of their starting body weight. The study authors noted that weight loss had not clearly plateaued in the groups receiving the 4mg and 6mg doses, suggesting the drug's full potential may not have been reached within the 48-week treatment period.
Ribupatide functions similarly to Mounjaro by mimicking hormones that regulate appetite and blood sugar, promoting a feeling of fullness and reducing hunger. For comparison, Wegovy, which contains semaglutide, has shown about 18.7 percent weight loss over 72 weeks, and Mounjaro (tirzepatide) has achieved approximately 22.5 percent weight loss over the same period, though direct comparisons with ribupatide have not yet been made.
Beyond weight reduction, ribupatide demonstrated additional health benefits. Researchers observed improvements in blood pressure, blood sugar control, and cholesterol levels. Systolic blood pressure decreased more significantly in ribupatide groups compared to the placebo, and triglycerides fell by 29 to 37 percent more. Insulin resistance also appeared to decrease, and total cholesterol levels dropped.
Common side effects reported were gastrointestinal issues, including nausea, vomiting, and diarrhea, affecting about half to two-thirds of participants depending on the dosage. Most cases were described as mild or moderate. The study's limitations included the relatively short treatment period and the young average age of participants, suggesting findings may not be generalizable to older populations.
Clinical trials for ribupatide are ongoing in the UK, with patients being recruited for phase three trials. These trials include comparisons with semaglutide and will assess the drug's efficacy and safety over an 18-month period in individuals with and without diabetes.